Analysis of laser-microdissected prostate cancer tissues reveals potential tumor markers

International Journal of Molecular Medicine

Volumn 28, Issue 4, 2011, Pages 605-611

  Adler, David ^a   Lindstrot, Andreas ^a   Buettner, Reinhard ^a   Wernert, Nicolas ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Microarray; Prostate cancer; Transcriptional regulation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN CREBBP; PROTEIN ITGA2; PROTEIN NBL1; PROTEIN TGM4; PROTEIN TMPRSS2; PROTEIN TTF3; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 79960769774     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.746     Document Type: Article

References (78)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Draisma G, Etzioni R, Tsodikov A, et al: Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101: 374-383, 2009.
3. Park JY: Promoter hypermethylation in prostate cancer. Cancer Control 17: 245-255, 2010.
4. Wu JN and Dall'Era MA: Active surveillance for localized prostate cancer - current practices and recommendations. Sci World J 10: 2352-2361, 2010.
5. Liang Y, Ankerst DP, Ketchum NS, et al: Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol 185: 104-110, 2011.
6. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
7. Arora R, Koch MO, Eble JN, Ulbright TM, Li L and Cheng L: Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100: 2362-2366, 2004. (Pubitemid 38657883)
8. Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM and Ruiter DJ: Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180: 295-299, 1996. (Pubitemid 26393679)
9. DeMarzo AM, Nelson WG, Isaacs WB and Epstein JI: Pathological and molecular aspects of prostate cancer. Lancet 361: 955-964, 2003. (Pubitemid 36332115)
10. Joshua AM, Evans A, Van der Kwast T, et al: Prostatic preneoplasia and beyond. Biochim Biophys Acta 1785: 156-181, 2008.
11. Isaacs W and Kainu T: Oncogenes and tumor suppressor genes in prostate cancer. Epidemiol Rev 23: 36-41, 2001. (Pubitemid 32906612)
12. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001. (Pubitemid 33741879)
13. Balk SP: Androgen receptor as a target in androgen-independent prostate cancer. Urology 60 (Suppl 1): S132-S139, 2002.
14. Koochekpour S: Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 12: 639-657, 2010.
15. Visakorpi T, Hyytinen E, Koivisto P, et al: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406, 1995.
16. Brown RS, Edwards J, Dogan A, et al: Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198: 237-244, 2002. (Pubitemid 35243882)
17. Grossmann ME, Huang H and Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687-1697, 2001. (Pubitemid 33130257)
18. Cummins JM, He Y, Leary RJ, et al: The colorectal microRNAome. Proc Natl Acad Sci USA 103: 3687-3692, 2006. (Pubitemid 43376616)
19. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005. (Pubitemid 41161233)
20. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006. (Pubitemid 43357945)
21. Calin GA, Ferracin M, Cimmino A, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801, 2005. (Pubitemid 41549891)
22. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006. (Pubitemid 43271657)
23. He H, Jazdzewski K, Li W, et al: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080, 2005. (Pubitemid 43049568)
24. Murakami Y, Yasuda T, Saigo K, et al: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537-2545, 2006.
25. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
26. Mattie MD, Benz CC, Bowers J, et al: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5: 24, 2006.
27. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135, 2007. (Pubitemid 47037493)
28. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
29. Heneghan HM, Miller N and Kerin MJ: MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol 10: 543-550, 2010.
30. Kim S, Huang W, Mottillo EP, et al: Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: enhanced surface expression and differential O-glycosylation of MT1-MMP. Biochim Biophys Acta 1803: 1287-1297, 2010.
31. Kong D, Li Y, Wang Z, et al: miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27: 1712-1721, 2009.
32. Kranenburg O: The KRAS oncogene: past, present, and future. Biochim Biophys Acta 1756: 81-82, 2005.
33. Lee JT, Lehmann BD, Terrian DM, et al: Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 7: 1745-1762, 2008. (Pubitemid 351988740)
34. Lee KH, Chen YL, Yeh SD, et al: MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 28: 3360-3370, 2009.
35. Lee YS, Kim HK, Chung S, Kim KS and Dutta A: Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem 280: 16635-16641, 2005. (Pubitemid 41389120)
36. Li T, Li D, Sha J, Sun P and Huang Y: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383: 280-285, 2009.
37. McCall P, Witton CJ, Grimsley S, Nielsen KV and Edwards J: Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer 99: 1296-1301, 2008.
38. Pearson HB, Phesse TJ and Clarke AR: K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res 69: 94-101, 2009.
39. Ren C, Ren CH, Li L, Goltsov AA and Thompson TC: Identification and characterization of RTVP1/GLIPR1-like genes, a novel p53 target gene cluster. Genomics 88: 163-172, 2006. (Pubitemid 44062273)
40. Sun T, Wang Q, Balk S, Brown M, Lee GS and Kantoff P: The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 69: 3356-3363, 2009.
41. Thompson TC: Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential. Yonsei Med J 51: 479-483, 2010.
42. Yoshimoto M, Cunha IW, Coudry RA, et al: FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97: 678-685, 2007. (Pubitemid 47339893)
43. Costa FF: Epigenomics in cancer management. Cancer Manag Res 2: 255-265, 2010.
44. Iacobuzio-Donahue CA: Epigenetic changes in cancer. Annu Rev Pathol 4: 229-249, 2009.
45. Perry AS, Watson RW, Lawler M and Hollywood D: The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol 7: 668-680, 2010.
46. Nelson WG, DeWeese TL and DeMarzo AM: The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 21: 3-16, 2002. (Pubitemid 35205190)
47. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
48. Lin SL, Chiang A, Chang D and Ying SY: Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14: 417-424, 2008. (Pubitemid 351397806)
49. Musiyenko A, Bitko V and Barik S: Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates protein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med 86: 313-322, 2008.
50. Varambally S, Cao Q, Mani RS, et al: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-1699, 2008.
51. Kumar-Sinha C, Tomlins SA and Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nature Rev 8: 497-511, 2008.
52. He J, Pan Y, Hu J, Albarracin C, Wu Y and Dai JL: Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther 6: 76-82, 2007. (Pubitemid 46294180)
53. Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648, 2005. (Pubitemid 41528150)
54. Furusato B, Tan SH, Young D, et al: ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 13: 228-237, 2010.
55. Watson D, Turner D, Scheiber M, Findlay V and Watson P: ETS transcription factor expression and conversion during prostate and breast cancer progression. Open Cancer J 3: 24-29, 2010.
56. Okuducu AF, Hahne JC, Von Deimling A and Wernert N: Laser-assisted microdissection, techniques and applications in pathology (Review). Int J Mol Med 15: 763-769, 2005.
57. Okuducu AF, Janzen V, Hahne JC, Ko Y and Wernert N: Influence of histochemical stains on quantitative gene expression analysis after laser-assisted microdissection. Int J Mol Med 11: 449-453, 2003.
58. Wellmann A, Wollscheid V, Lu H, et al: Analysis of microdissected prostate tissue with ProteinChip arrays: A way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med 9: 341-347, 2002.
59. Kohn EC: Invasion and metastasis: biology and clinical potential. Pharmacol Ther 52: 235-244, 1991.
60. Duffy MJ, McGowan PM and Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol 214: 283-293, 2008. (Pubitemid 351212383)
61. Duffy MJ: Cancer metastasis: biological and clinical aspects. Ir J Med Sci 167: 4-8, 1998.
62. Varga AE, Stourman NV, Zheng Q, et al: Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta. Oncogene 24: 5043-5052, 2005. (Pubitemid 41129082)
63. Bandyopadhyay S, Pai SK, Hirota S, et al: PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res 64: 7655-7660, 2004. (Pubitemid 39446890)
64. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
65. Borg A, Sandberg T, Nilsson K, et al: High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92: 1260-1266, 2000. (Pubitemid 30627734)
66. Castellano M, Pollock PM, Walters MK, et al: CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 57: 4868-4875, 1997. (Pubitemid 27468996)
67. Cobbers JM, Wolter M, Reifenberger J, et al: Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 8: 263-276, 1998. (Pubitemid 28186064)
68. Perez-Stable CM, Pozas A and Roos BA: A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Mol Cell Endocrinol 167: 43-53, 2000.
69. Mehra R, Varambally S, Ding L, et al: Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 65: 11259-11264, 2005. (Pubitemid 41821679)
70. Giles RH, Peters DJ and Breuning MH: Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14: 178-183, 1998. (Pubitemid 28244241)
71. Zutter MM, Mazoujian G and Santoro SA: Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 137: 863-870, 1990. (Pubitemid 20337801)
72. Enomoto H, Ozaki T, Takahashi E, et al: Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus. Oncogene 9: 2785-2791, 1994. (Pubitemid 24296752)
73. Asmann YW, Kosari F, Wang K, Cheville JC and Vasmatzis G: Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res 62: 3308-3314, 2002. (Pubitemid 34602429)
74. Dubbink HJ, Verkaik NS, Faber PW, Trapman J, Schroder FH and Romijn JC: Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J 315: 901-908, 1996. (Pubitemid 26147620)
75. Thielen JL, Volzing KG, Collier LS, Green LE, Largaespada DA and Marker PC: Markers of prostate region-specific epithelial identity define anatomical locations in the mouse prostate that are molecularly similar to human prostate cancers. Differentiation 75: 49-61, 2007. (Pubitemid 46115413)
76. Garraway IP, Seligson D, Said J, Horvath S and Reiter RE: Trefoil factor 3 is overexpressed in human prostate cancer. Prostate 61: 209-214, 2004. (Pubitemid 39350442)
77. Rickman DS, Chen YB, Banerjee S, et al: ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12: 1031-1040, 2010.
78. Vaarala MH, Porvari K, Kyllonen A, Lukkarinen O and Vihko P: The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer 94: 705-710, 2001. (Pubitemid 33035691)